Q1 2025 Cytokinetics Inc Earnings Call Transcript

May 6, 2025 / 08:30 PM GMT

Transcript 10-Q8-K

Key Points

Positve

Cytokinetics Inc (CYTK) reported a strong start to the year, laying a solid foundation for increased momentum towards potential commercialization.
The company completed patient enrollment for the Acacia HCM trial months ahead of schedule, indicating strong interest and participation.
Cytokinetics Inc (CYTK) has a robust cash position with approximately $1.1 billion in cash equivalents and investments, providing financial stability.
The company is advancing regulatory activities outside the US, with potential approval by the EMA expected in the first half of 2026.
Cytokinetics Inc (CYTK) is making significant progress in commercial readiness activities, including Salesforce recruiting and launch planning.

Negative

The FDA extended the PDUFA date for the NDA for Aficaton, delaying potential approval to December 26, 2025.
The submission of a REMS for Aficaton was required by the FDA, constituting a major amendment and causing a three-month extension.
R&D expenses increased significantly, from $81.6 million in Q1 2024 to $99.8 million in Q1 2025, impacting financial results.
The company reported a net loss of $161.4 million for Q1 2025, compared to a net loss of $135.6 million for the same period in 2024.
There is uncertainty and investor concern regarding the REMS submission process and its impact on the approval timeline.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CYTK.OQ - Cytokinetics Inc
Q1 2025 Cytokinetics Inc Earnings Call
May 06, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Cytokinetics first quarter 2025 conference call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode.

At the company's request, we will open the call to questions after the presentation.

We will allow for only one question per participant.

I will now turn the call over to Diane Weiser, cytokinetic senior Vice President of corporate affairs. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon and thanks for joining us on the call

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.